论文部分内容阅读
应用放免法检测２２例健康人（对照组）、９例喉部良性肿瘤和２８例喉癌患者血浆６－ｋｅｔｏ－ＰＧＦ１α和ＴＸＢ２的含量。结果表明喉部良性肿瘤患者血浆６－ｋｅｔｏ－ＰＧＦ１α和ＴＸＢ２的含量分别为对照组均值的１．３３和１．２４倍，而喉癌组则分别为３．２８和３．９４倍，且良性肿瘤与喉癌组间比较，二者均Ｐ＜０．０１，呈显著性差异。喉癌组检测值超过对照组的阳性率分别为８５．７％和７５．０％。喉癌患者血浆６－ｋｅｔｏ－ＰＧＦ１α和ＴＸＢ２含量的测定有助于提高喉癌的检出率，有利于良、恶性肿瘤的鉴别诊断。
The levels of 6-keto-PGF1α and TXB2 in 22 healthy subjects (control group), 9 benign tumors of the larynx and 28 laryngeal carcinomas were detected by radioimmunoassay. The results showed that the plasma levels of 6-keto-PGF1α and TXB2 in patients with benign laryngeal tumors were 1.33 and 1.24 times of those in the control group, while those in laryngeal cancer were 3.28 and 3.94 times, respectively, and benign Tumor and laryngeal cancer between groups, both P <0.01, showed significant differences. The detection rate of laryngeal cancer over the control group were 85.7% and 75.0% respectively. The determination of plasma 6-keto-PGF1α and TXB2 levels in laryngeal cancer patients will be helpful to improve the detection rate of laryngeal cancer and be helpful for the differential diagnosis of benign and malignant tumors.